

Leeds Institute of Cardiovascular and Metabolic Medicine

Discovery and Translational Science Department
LIGHT Laboratories
Clarendon Way
University of Leeds
Leeds, LS2 9JT

T +44 (0) 113 343 7768
E h.philippou@leeds.ac.uk



UNIVERSITY OF LEEDS

20th August 2020

Dear Dr Kim,

I would gratefully like to thank Dr Kolev for nominating me for election as a council members (class 2025) for the ISFP. If elected I would be delighted to serve on the council for the ISFP. My career started at Imperial College where I worked for 10 years on characterisation of mechanisms of thrombosis in various clinical circumstance. In 2002, I moved to the University of Leeds where my focus turned towards the end-stages of coagulation around fibrinogen, Factor XIII and fibrinolysis.

Between, 2012-2015, I was Chairman of the FXIII and Fibrinogen Standardization Subcommittee (SSC) of the International Society of Thrombosis and Haemostasis. In this role, we collaborated with the Fibrinolysis SSC (Chairman: Dr Nicola Mutch) in a study initiated by Dr Marlien Pieters (An international study on the feasibility of a standardized combined plasma clot turbidity and lysis assay: communication from the SSC of the ISTH. Pieters M, Philippou H, Undas A, de Lange Z, Rijken DC, Mutch NJ; Subcommittee on Factor XIII and Fibrinogen, and the Subcommittee on Fibrinolysis) resulting in the first joint SSC manuscript between the two subcommittees.

I attended my first ISFP meeting in Melbourne in 2004, organised by Prof Rob Metcalf. Thereafter, I regularly attended the ISFP conferences and in 2012, I supported the organisation of the ISFP where I was vice-President of the organising committee alongside the President, Dr Colin Longstaff (which also included overlap with the Fibrinogen workshop). If I was elected I would be delighted to organise a conference in Leeds or surrounding area.

I am currently a Director Founder of a spin-out company that is developing a novel anticoagulant with predicted minimal bleeding risk. In this position I have led the overall programme and raised multi-£m of Life Science Investor and Government grant funding for the company. We are now recruiting a new CEO to take over the leadership of the company, which will free my time to pursue my next passion of developing improved thrombolytic therapies to improve patient outcomes.

The ISFP is a very important Society to myself and others in the field and I will do my utmost to support its activities.

I very much appreciate this opportunity to be considered as a member of the ISFP council.

With kind regards



Helen Philippou

Helen Philippou
Professor of Translational Medicine